6 results match your criteria: "Lions Gate Hospital - Vancouver Coastal Health[Affiliation]"
Identifying clinical and proteomic markers for early diagnosis and prognosis prediction of major psychiatric disorders.
J Affect Disord
January 2025
Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada; Department of Psychiatry, Lions Gate Hospital - Vancouver Coastal Health, British Columbia, Canada. Electronic address:
Background: To clarify if blood proteins can predict disease progression among individuals at clinical high-risk of severe mental illness (CHR-SMI), we developed a statistical model incorporating clinical and blood protein markers to distinguish the transition group (who developed severe mental illness) (CHR-SMI-T) and from non-transition group (CHR-SMI-NT) at baseline.
Methods: Ninety individuals (74 at CHR-SMI: 16 patients) were monitored for ≤4 years and were the focus of predictive models. Three predictive models (1 [100 clinical variables], 2 [158 peptides], and 3 [100 clinical variables +158 peptides]) were evaluated using area under the receiver operating characteristic (AUROC) values.
Genome-wide association study and polygenic risk score analysis for schizophrenia in a Korean population.
Asian J Psychiatr
December 2024
Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada; Department of Psychiatry, Lions Gate Hospital - Vancouver Coastal Health Authority, British Columbia, Canada. Electronic address:
Article Synopsis
- A study focused on identifying genetic variants linked to schizophrenia specifically in the Korean population, as previous large-scale studies mainly involved individuals of European ancestry.
- Researchers recruited 1,670 schizophrenia patients and 2,271 healthy controls, testing over 6.6 million SNPs, and discovered a significant new variant (rs2423464) associated with the condition.
- The polygenic risk scores (PRS) derived from a combination of East Asian and European GWASs were more effective in explaining the genetic variance in schizophrenia among Koreans than those from single-ancestry studies.
Exploring intra-diagnosis heterogeneity and inter-diagnosis commonality in genetic architectures of bipolar disorders: association of polygenic risks of major psychiatric illnesses and lifetime phenotype dimensions.
Psychol Med
May 2024
Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.
Article Synopsis
- The study investigates the relationship between phenotypically diverse subtypes of bipolar disorder (BD) and genetic factors, suggesting that different subtypes may share a genetic basis with other psychiatric disorders.* -
- Researchers analyzed six specific "lifetime phenotype dimensions" of BD and their associations with polygenic risk scores (PRS) derived from various populations, revealing distinct patterns for each dimension.* -
- The findings support the idea of genetic diversity in BD and indicate shared genetic risks with other mental illnesses, highlighting the need for more detailed research across different populations to understand these relationships better.*
Integrated proteomic and genomic analysis to identify predictive biomarkers for valproate response in bipolar disorder: a 6-month follow-up study.
Int J Bipolar Disord
May 2024
Department of Neuropsychiatry, Seoul National University Hospital, 101, Daehak-Ro, Jongno-Gu, Seoul, 03080, Republic of Korea.
Background: Several genetic studies have been undertaken to elucidate the intricate interplay between genetics and drug responses in bipolar disorder (BD). However, there has been notably limited research on biomarkers specifically linked to valproate, with only a few studies investigating integrated proteomic and genomic factors in response to valproate treatment. Therefore, this study aimed to identify biological markers for the therapeutic response to valproate treatment in BD.
View Article and Find Full Text PDFThe characteristics and clinical outcomes of a pluripotent high-risk group with the potential to develop a diverse range of psychiatric disorders.
J Psychiatr Res
June 2024
Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Republic of Korea; Department of Psychiatry and Behavioral Science, Seoul National University College of Medicine, Seoul, Republic of Korea; Institute of Human Behavioral Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea.
Background: Recent studies have indicated that clinical high risk for psychosis (CHR-P) is highly specific for psychotic disorders other than pluripotential to various serious mental illnesses. However, not all CHR-P develop psychotic disorder only, and psychosis can occur in non-psychotic disorders as well. Our prospective cohort study aims to investigate the characteristics and clinical outcomes of a pluripotent high-risk group with the potential to develop a diverse range of psychiatric disorders.
View Article and Find Full Text PDFProteomic profiling in the progression of psychosis: Analysis of clinical high-risk, first episode psychosis, and healthy controls.
J Psychiatr Res
January 2024
Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Republic of Korea; Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea; Institute of Human Behavioral Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea. Electronic address:
Background And Hypothesis: Recent evidence has highlighted the benefits of early detection and treatment for better clinical outcomes in patients with psychosis. Biological markers of the disease have become a focal point of research. This study aimed to identify protein markers detectable in the early stages of psychosis and indicators of progression by comparing them with those of healthy controls (HC) and first episode psychosis (FEP).
View Article and Find Full Text PDF